300639.SZ
凯普生物
SZSE · Healthcare · C 制造业 · CN
CNY 5.97
−3.40%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 661.4M | 669.6M | 815.5M | 1.1B | 5.6B |
| Cost of Revenue | 367.1M | 365.2M | 426.7M | 430.4M | 1.7B |
| Gross Profit | 294.3M | 304.5M | 388.8M | 674.0M | 3.9B |
| Operating Expenses | |||||
| R&D Expense | 58.9M | 62.4M | 85.6M | 136.3M | 247.3M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 206.4M | 206.5M | 221.2M | 253.4M | 387.5M |
| Selling & Marketing Expense | 168.1M | 166.9M | 260.8M | 279.1M | 460.2M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 388.7M | 409.5M | 579.8M | 667.6M | 1.1B |
| Cost and Expenses | 755.8M | 774.7M | 1.0B | 1.1B | 2.8B |
| Operating Income (EBIT) | (118.7M) | (156.4M) | (821.7M) | 42.6M | 2.2B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (128.2M) | (169.3M) | (833.0M) | 36.8M | 2.1B |
| Income Tax Expense | 16.1M | 13.0M | 117.4M | (31.7M) | 326.1M |
| Bottom Line | |||||
| Net Income | (106.4M) | (130.9M) | (654.9M) | 140.5M | 1.7B |
| Earnings from Cont. Ops | (144.3M) | (182.3M) | (950.4M) | 68.5M | 1.8B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (106.4M) | (130.9M) | (654.9M) | 140.5M | 1.7B |
| Per Share | |||||
| Basic EPS | (CN¥0.17) | (CN¥0.21) | (CN¥1.02) | CN¥0.25 | CN¥2.62 |
| Diluted EPS | (CN¥0.17) | (CN¥0.21) | (CN¥1.02) | CN¥0.25 | CN¥2.62 |
| Revenue Per Share | CN¥1.02 | CN¥1.07 | CN¥1.27 | CN¥1.97 | CN¥8.50 |
| Shares | |||||
| Basic Shares Outstanding | 650.4M | 623.5M | 642.0M | 561.9M | 658.8M |
| Diluted Shares Outstanding | 650.4M | 623.5M | 642.0M | 561.9M | 658.8M |
| Profitability Metrics | |||||
| EBITDA | — | 15.2M | (632.6M) | 222.1M | 2.4B |
| D&A | — | 171.6M | 189.1M | 179.5M | 181.5M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026